Orchestra BioMed Expected to Post 78% Revenue Decline, 43-Cent Loss in Q1
OBIO sits 80% above its 52-week low of $2.2.
Summary
Analysts anticipate Orchestra BioMed Holdings will report a significant financial downturn for Q1 2026, with an expected 78% year-over-year decrease in revenue to $190.75 thousand and a loss of 43 cents per share. This earnings preview sets a low bar for the upcoming May 4 report, highlighting operational challenges despite recent positive news like the FDA Breakthrough Device Designation. While the company's last 10-K indicated an extended cash runway, these consensus estimates suggest continued unprofitability and a substantial drop in top-line performance. Traders will closely watch the actual Q1 results to see if the company can outperform these lowered expectations, which could significantly impact the stock.
At the time of this announcement, OBIO was trading at $3.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $232.3M. The 52-week trading range was $2.20 to $5.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.